Biomolecules | Free Full-Text | Dostarlimab: A Review
Dostarlimab in Advanced/Recurrent Mismatch Repair Deficient/Microsatellite Instability High or Proficient/Stable Endometrial Can
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I ...
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis - Gynecologic Oncology
Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab for recurrent or advanced dMMR endometrial cancer patients - Oncology Central
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in
Dostarlimab subject to accelerated FDA approval for the treatment of advanced dMMR endometrial cancer | VJOncology
272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study | International Journal of Gynecologic Cancer
Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab for recurrent or advanced dMMR endometrial cancer patients - Oncology Central
PDF) 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer - Plain Language Summaries
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 | International Journal of Gynecologic Cancer
Biosensors | Free Full-Text | Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
Immune-Related End Points Consistent With Traditional Measurements of Dostarlimab in Non-Endometrial dMMR Solid Tumors
Expert Commentary On The Product Profile Of Dostarlimab
Antitumor Activity of Dostarlimab in Patients with Mismatch Repair–Deficient (dMMR) Tumors: a Combined Analysis of 2 Cohorts i
From New Molecular Insights to New Treatment Options in Endometrial Cancer | Published in healthbook TIMES Oncology Hematology
ESGO 2022: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study
The Time Course of Adverse Events During Dostarlimab Treatment in Patients with Recurrent or Advanced Endometrial Cancer in the
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer | Future Oncology
Cancer Trial Results
Cancer Trial Results
Dostarlimab: First Approval | SpringerLink
GARNET Study Suggests Dostarlimab Promising for Uterine/Endometrial Cancer - CancerConnect
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I ...
